Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint to Detect Improvements in Pulmonary Fibrosis Patients

WARREN, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse® Phase 2b clinical trial (iNO-PF) for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) that supports actigraphy as a clinically meaningful endpoint will be the subject of a poster presentation at the 13th Annual Pulmonary Vascular Research Institute World Congress on Pulmonary Vascular Disease, which will take place January 31 through February 3, 2019, in Barcelona, Spain.

Read Full Article

Published date: January 28th, 2019
By: Bellerophon Therapeutics, Inc.

Back to Blog

Recent Articles

ActiGraph Awards Research Grants to Advance Digital Clinical Measures

PENSACOLA, FL, March 1, 2023–ActiGraph, a pioneer and leading provider of digital health...

ActiGraph Partners with PDH to Advance DHTs in Clinical Research

PENSACOLA, FL, April 3, 2023–ActiGraph, a leading provider of wearable technology and scientific...

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with integration

Philadelphia, PA – November 14, 2019:Signant Health, formerly CRF Health and Bracket, is proud to...